High-risk patients taking evolocumab had a 20% lower risk of death compared to those on placebo, according to a Mass General Brigham study. The study found that intensive LDL-C lowering with evolocumab was associated with lower risk of heart attack and stroke, as well as improved survival in high-risk patients without a prior CV event.
Researchers found that individuals with higher modifiable risk factors, such as high blood pressure and obesity, have more widespread plaque buildup and unstable plaques prone to rupture. The study's findings highlight the importance of early intervention to control these risk factors and prevent future events.
Researchers developed a new polygenic risk score (PRS) that estimates a person's inherited risk for eight common cardiovascular conditions. The test combines information from many genetic variants and evaluates a person's risk for coronary artery disease, atrial fibrillation, type 2 diabetes, and more.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 32% of the US adult population. Obesity was identified as the strongest independent MRF among Asians, Whites, and Hispanics, particularly in individuals younger than 50 years, whereas hypertension was the strongest independent MRF in Blacks.
Researchers found that CD47 knockdown improves glucose homeostasis and alleviates dyslipidemia in aged male mice by reducing visceral fat and enhancing brown fat tissue function. This breakthrough suggests CD47 as a key regulator of age-related metabolic dysfunction.
A substantial proportion of asymptomatic individuals in Greater Vancouver have undetected MASLD and significant fibrosis. Age, male sex, ethnicity, cardiac disease, diabetes, hypertension, and obesity were significantly associated with fibrosis.
Decreased gut bacterial diversity was found in patients with NAFLD, while Faecalibacterium and Ruminococcus 2 were associated with the disease. The study identified a combination of microbiomes and biochemical indexes that distinguished NAFLD from normal livers.
Research reveals that FoxO6 upregulates ApoC3, leading to increased lipid accumulation and liver damage in aged rats on a high-fat diet. The study suggests that targeting this pathway may offer therapeutic strategies against hepatic steatosis.
Researchers at Michigan Medicine found that telemedicine patients with hyperlipidemia experienced significant decreases in LDL and non-HDL cholesterol levels. Virtual appointments were shown to be as effective as in-person visits in improving cholesterol levels, overcoming barriers to access for patients.
A study of nearly 13,000 young US adults found rising diabetes and obesity rates, while hypertension remained stable. The data reveal a high burden of cardiovascular risk factors among this demographic, with Black, Hispanic, and Mexican American individuals disproportionately affected.
Researchers at Osaka University found that disasters and pandemics increase major non-communicable diseases and mental disorders, especially among certain age groups. The study highlights the need for improved post-disaster health policies and prevention strategies to mitigate these effects.
A Wayne State University School of Medicine researcher has been awarded a $2.3 million grant to explore the mechanism by which circadian stress regulates RNA modification associated with non-alcoholic fatty liver disease and hyperlipidemia. The study aims to shed light on developing therapeutics for lipid-associated metabolic disease.
Research suggests that RA patients who receive combined care from primary-care physicians and rheumatologists are more likely to be screened for hyperlipidemia. This study found that 47% of patients seeing both a PCP and rheumatologist were screened, compared to 42% of those seeing only a PCP.
Research from Tufts University reveals that hyperlipidemia, high cholesterol and high triglycerides, accelerates heart-transplant rejection in mice. The studies, published online in the American Journal of Transplantation, found that mice fed a high-fat diet rejected their transplants faster than those on a lower-fat diet.
A new study reveals benfluorex, a fenfluramine derivative used in France from 1976 to 2009, was responsible for approximately 3,100 hospitalizations and 1,300 deaths. The use of this drug led to significant changes in the French regulatory system.
A large study reveals that co-administration of Zetia and fenofibrate significantly lowers LDL cholesterol, non-HDL cholesterol, and apo B to a greater extent than fenofibrate alone in mixed hyperlipidemia patients. This improvement is also seen in HDL cholesterol levels.
A study of 3000 children aged 5-17 found a clear relationship between abdominal fat and abnormal serum lipids and insulin levels. This suggests that childhood obesity may predict later development of diabetes and heart disease.